Ipsen
 |
|
| Public (Euronext: IPN) | |
| Industry | Pharmaceutical |
| Founded | 1929 |
| Headquarters | Paris, France |
|
Key people
|
Marc de Garidel (Non-executive Chairman) David Meek (Chief Executive Officer) |
| Products |
|
|
Number of employees
|
4,900 |
| Website | www.ipsen.com |
Marc de Garidel (Non-executive Chairman)
Ipsen is a French pharmaceutical company headquartered in Paris, France. It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders. It is publicly traded on the Euronext Paris as part of the SBF 120 index.
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.4 billion in 2015. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.
The Beaufour family, which ranks as the 42nd richest family in France, still owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.
The Board of Directors of Ipsen has appointed David Meek as Chief Executive Officer, effective July 18, 2016. On this date, Marc de Garidel will assume the role of non-executive chairman and will continue to serve the Board of Directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.
In 2015, Ipsen spent close to €200 million—13% of consolidated sales—on research and development.
In February 2015, the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex’s lead multiple sclerosis compound, VSN16R.
in October 2016, European Commission approves Ipsen’s Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
...
Wikipedia